Drug Trial Radar · NCT05428969
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
181
Planned (sponsor's estimate)
Start
Jun 2, 2022
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Faron Pharmaceuticals LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase 1 aims to identify the recommended phase 2 dose (RP2D) of bexmarilimab based on safety, tolerability and pharmacological activity; Phase 2 will investigate the preliminary efficacy of the combination treatment in selected indications from Phase 1.
Conditions
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndromes
- Relapsed/Refractory AML
Interventions
BexmarilimabDrug
Intravenous
AzacitidineDrug
As per label, subcutaneous
VenetoclaxDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reporting of incidence and frequency of dose limiting toxicities (DLTs).Time frame: From study start to end of Cycle 1 (each cycle is 28 days)
- Frequency and severity based on NCI-CTCAE grading of treatment emergent AEs and serious adverse events (SAE).Time frame: From study start to 30 days after end of treatment (EOT)
- Complete response (CR) rate for MDS and CMML-2.Time frame: From study start to 30 days after EOT
- Overall response rate (ORR) for MDS and CMML failure to prior HMA.Time frame: From study start to 30 days after EOT
- Complete remission with incomplete blood recovery (CRi) for r/r AML.Time frame: From study start to 30 days after EOT
- Minimal residual disease (MRD) status for newly diagnosed AML.Time frame: From study start to 30 days after EOT
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
Yale Cancer Center
New Haven, Connecticut
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
University of Texas, MD Anderson Cancer Center
Houston, Texas
Helsinki University Hospital
Helsinki, Finland
Kuopio University Hospital
Kuopio, Finland
Oulu University Hospital
Oulu, Finland
Tampere University Hospital
Tampere, Finland
The Christie NHS Foundation Trust
Manchester, United Kingdom
Royal Cornwall Hospitals NHS Trust
Truro, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.